Pediatric CML
Co-chair
Professor Meinolf Suttorp (Germany)
Co-chair
Professor Nirmalya Roy Moulik (India)
Chair's Overview
Professor Meinolf Suttorp
Pediatric Hematology – Oncology, Medical Faculty, Technical University, Dresden, Germany
Dr Nirmalya Roy Moulik
Professor of Paediatric Oncology, Tata Memorial Hospital, Mumbai, India
The Difference Between Adult and Pediatric CML
Dr Deepam Pushpam
Assistant Professor, Department of Medical Oncology, All India Institute of Medical Sciences, Delhi, India
Predisposition and Genetic Factors in Pediatric CML
Professor Markus Metzler
Faculty of Medicine, Friedrich-Alexander University, Erlangen-Nurnberg, Germany
Management of Pediatric CML in the Resource-Constrained Setting
Dr Nirmalya Roy Moulik
Professor, Pediatric Oncology, Tata Memorial Hospital, Mumbai, India
Impact of Tyrosine Kinase Inhibitors (TKIs) on Growth and Endocrine Function in Children with CML
Professor Meinolf Suttorp
Pediatric Hematology – Oncology, Medical Faculty, Technical University, Dresden, Germany
Treatment Recommendations for Pediatric CML - Chronic Phase
Professor Frédéric Millot
Chairman of the CML committee of the I-BFM Study Group, Coordinator of the International Registry of Childhood CML, CHU de Poitiers, Poitiers, France
Treatment recommendations in pediatric CML blast phase
Dr Stephanie Sembill
Department of Hematology and Oncology, University Hospital, Erlangen, Germany
Treatment Free Remission in Pediatric CML
Professor Nobuko Hijiya
Herbert and Florence Irving Professor, Section Head of Pediatric Oncology Pediatric Hematology/Oncology/Stem Cell Transplant, Columbia University, Irving Medical Center, New York, NY, USA
Tyrosine kinase inhibitor toxicity in pediatric CML
Dr Maaike Luesink
Pediatric Oncologist, Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands
Parenting in children with CML
Professor Meinolf Suttorp
Pediatric Hematology – Oncology, Medical Faculty, Technical University, Dresden, Germany